Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645358 | 0.90 | GPR27 (0.37) | NR3C1TRPV4GPR27EPHX2 | |
| SCHEMBL6643611 | 0.84 | IRAK4 (0.37) | IRAK4EPHX2 | |
| SCHEMBL6645551 | 0.83 | KMT2A (0.38) | SGMS2IRAK4GPR27LRRK2 | |
| SCHEMBL6643608 | 0.82 | IRAK4 (0.39) | DGAT1NR3C1FGFR3IRAK4TRPV1 | |
| SCHEMBL6648929 | 0.81 | TAS1R3 (0.42) | NR3C1GPR27 | |
| SCHEMBL6647719 | 0.79 | F2 (0.31) | — | |
| SCHEMBL6645363 | 0.78 | IRAK4 (0.34) | TRPV4IRAK4 | |
| SCHEMBL6643944 | 0.78 | DGAT1 (0.32) | DGAT1TRPV4 | |
| SCHEMBL6646621 | 0.76 | PKM (0.38) | — | |
| SCHEMBL6647477 | 0.76 | MEN1 (0.38) | NR3C1TRPV4GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | DGAT1 487/4885NR3C1 22/4885TRPV4 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.